A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
NCT ID: NCT05780736
Last Updated: 2024-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
33 participants
OBSERVATIONAL
2023-08-04
2024-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
NCT06499298
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NCT04594811
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
NCT03604991
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
NCT02743494
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
NCT03044613
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must have confirmed diagnosis of resected early stage (Stage II/III) EC or GEJC (histologically or cytologically confirmed stage)
3. Physician decision to treat the participant with adjuvant nivolumab (according to the local label as per country-specific regulations) must be made prior to and independently of participation in the study
Exclusion Criteria
2. Prior treatment with immuno-oncologic agents, including nivolumab, for any indication
3. Participants with a current primary diagnosis of a cancer other than EC or GEJC that requires systemic or other treatment, or has not been treated curatively (as per discretion of the investigator)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PPD Development, LP
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Pacific Central Coast Health Centers - San Luis Obispo Oncology and Hematology Health Center
San Luis Obispo, California, United States
Mission Cancer Center
Santa Maria, California, United States
Saint Alphonsus Regional Medical Center
Boise, Idaho, United States
UPMC Hillman Cancer Center
Westwood, Kansas, United States
University Of Louisville
Louisville, Kentucky, United States
Weill Cornell Medical College
New York, New York, United States
Local Institution - 0009
Dallas, Texas, United States
William Beaumont Army Medical Center
Fort Bliss, Texas, United States
The University Of Texas
Houston, Texas, United States
Baylor Scott and White Health
Temple, Texas, United States
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Klinikum Munchen-Bogenhausen
München, Bavaria, Germany
Klinikum Kassel
Kassel, Hesse, Germany
Onkologische Schwerpunktpraxis Dres. Ingo Zander und Eyck von der Heyde
Hanover, Lower Saxony, Germany
Alexianer, Maria-Hilf-Krankenhaus
Essen, North Rhine-Westphalia, Germany
Oncologianova GmbH
Recklinghausen, North Rhine-Westphalia, Germany
Local Institution - 0006
Mainz, Rhineland-Palatinate, Germany
Universitätsklinikum Bonn
Bonn, Saarland, Germany
Local Institution - 0033
Homburg, Saarland, Germany
CaritasKlinikum Saarbruecken.
Saarbrücken, Saarland, Germany
Klinikum Chemnitz Ggmbh
Chemnitz, Saxony, Germany
BAG Freiberg-Richter, Jacobash, Illmer, Wolf
Dresden, Saxony, Germany
Universitätsklinik Magdeburg
Magdeburg, Saxony-Anhalt, Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA209-6KX
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.